AVITA MEDICAL INC (RCEL)
US05380C1027 - Common Stock
Overall RCEL gets a fundamental rating of 3 out of 10. We evaluated RCEL against 564 industry peers in the Biotechnology industry. RCEL has a bad profitability rating. Also its financial health evaluation is rather negative. RCEL is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year RCEL has reported negative net income.
In the past year RCEL has reported a negative cash flow from operations.
1.2 Ratios
RCEL has a worse Return On Assets (-70.72%) than 66.79% of its industry peers.
RCEL has a worse Return On Equity (-468.81%) than 79.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -70.72% | ||
| ROE | -468.81% | ||
| ROIC | N/A |
ROA(3y)-26.67%
ROA(5y)N/A
ROE(3y)-42.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RCEL's Gross Margin of 86.46% is amongst the best of the industry. RCEL outperforms 89.77% of its industry peers.
In the last couple of years the Gross Margin of RCEL has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for RCEL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 86.46% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.45%
GM growth 5YN/A
2. Health
2.1 Basic Checks
RCEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RCEL has been increased compared to 1 year ago.
The debt/assets ratio for RCEL is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -3.93, we must say that RCEL is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of RCEL (-3.93) is comparable to the rest of the industry.
RCEL has a Debt/Equity ratio of 3.48. This is a high value indicating a heavy dependency on external financing.
RCEL's Debt to Equity ratio of 3.48 is on the low side compared to the rest of the industry. RCEL is outperformed by 83.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.48 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.93 |
ROIC/WACCN/A
WACC10.54%
2.3 Liquidity
RCEL has a Current Ratio of 3.73. This indicates that RCEL is financially healthy and has no problem in meeting its short term obligations.
RCEL's Current ratio of 3.73 is in line compared to the rest of the industry. RCEL outperforms 43.81% of its industry peers.
A Quick Ratio of 3.37 indicates that RCEL has no problem at all paying its short term obligations.
RCEL has a Quick ratio of 3.37. This is comparable to the rest of the industry: RCEL outperforms 42.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.73 | ||
| Quick Ratio | 3.37 |
3. Growth
3.1 Past
The earnings per share for RCEL have decreased strongly by -66.42% in the last year.
RCEL shows a strong growth in Revenue. In the last year, the Revenue has grown by 32.22%.
Measured over the past years, RCEL shows a very strong growth in Revenue. The Revenue has been growing by 52.07% on average per year.
EPS 1Y (TTM)-66.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.35%
Revenue 1Y (TTM)32.22%
Revenue growth 3Y52.07%
Revenue growth 5YN/A
Sales Q2Q%43.25%
3.2 Future
RCEL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.01% yearly.
The Revenue is expected to grow by 27.93% on average over the next years. This is a very strong growth
EPS Next Y-28.96%
EPS Next 2Y19.52%
EPS Next 3Y22.03%
EPS Next 5Y21.01%
Revenue Next Year36.38%
Revenue Next 2Y44.35%
Revenue Next 3Y37.63%
Revenue Next 5Y27.93%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RCEL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RCEL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RCEL's earnings are expected to grow with 22.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.52%
EPS Next 3Y22.03%
5. Dividend
5.1 Amount
No dividends for RCEL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AVITA MEDICAL INC
NASDAQ:RCEL (1/3/2025, 8:00:01 PM)
After market: 13.24 0 (0%)13.24
+0.45 (+3.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners24.64%
Inst Owner Change0.22%
Ins Owners0.9%
Ins Owner Change1.48%
Market Cap347.15M
Analysts77.14
Price Target17.34 (30.97%)
Short Float %4.46%
Short Ratio10.73
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.43%
Min EPS beat(2)-39.31%
Max EPS beat(2)-13.56%
EPS beat(4)1
Avg EPS beat(4)-19.36%
Min EPS beat(4)-51.24%
Max EPS beat(4)26.68%
EPS beat(8)3
Avg EPS beat(8)-11.84%
EPS beat(12)7
Avg EPS beat(12)3.2%
EPS beat(16)9
Avg EPS beat(16)-0.51%
Revenue beat(2)1
Avg Revenue beat(2)-0.12%
Min Revenue beat(2)-1.35%
Max Revenue beat(2)1.11%
Revenue beat(4)1
Avg Revenue beat(4)-1.43%
Min Revenue beat(4)-4.02%
Max Revenue beat(4)1.11%
Revenue beat(8)5
Avg Revenue beat(8)0.39%
Revenue beat(12)8
Avg Revenue beat(12)4.21%
Revenue beat(16)11
Avg Revenue beat(16)6.08%
PT rev (1m)0%
PT rev (3m)11.84%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-84.02%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-15.24%
Revenue NY rev (1m)3.76%
Revenue NY rev (3m)0.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.78 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 28.39 | ||
| P/tB | 29.83 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.23
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-2.27
FCFYN/A
OCF(TTM)-1.97
OCFYN/A
SpS2.29
BVpS0.47
TBVpS0.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -70.72% | ||
| ROE | -468.81% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 86.46% | ||
| FCFM | N/A |
ROA(3y)-26.67%
ROA(5y)N/A
ROE(3y)-42.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.45%
GM growth 5YN/A
F-Score3
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.48 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 873.19% | ||
| Cap/Sales | 13.07% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.73 | ||
| Quick Ratio | 3.37 | ||
| Altman-Z | -3.93 |
F-Score3
WACC10.54%
ROIC/WACCN/A
Cap/Depr(3y)153.32%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.69%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-66.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.35%
EPS Next Y-28.96%
EPS Next 2Y19.52%
EPS Next 3Y22.03%
EPS Next 5Y21.01%
Revenue 1Y (TTM)32.22%
Revenue growth 3Y52.07%
Revenue growth 5YN/A
Sales Q2Q%43.25%
Revenue Next Year36.38%
Revenue Next 2Y44.35%
Revenue Next 3Y37.63%
Revenue Next 5Y27.93%
EBIT growth 1Y-62.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28.47%
EBIT Next 3Y22.14%
EBIT Next 5Y27.38%
FCF growth 1Y-183.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-151.31%
OCF growth 3YN/A
OCF growth 5YN/A